China's Shanghai Pharma Raises $550 Million From U.S. For IPO
This article was originally published in PharmAsia News
Executive Summary
Shanghai Pharmaceuticals of China reportedly amassed $550 million from four U.S. investors for its upcoming initial public offering on the Hong Kong stock exchanges